Boltwood Capital Management Sells 3,688 Shares of Pfizer Inc. (NYSE:PFE)

Boltwood Capital Management decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 6.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,649 shares of the biopharmaceutical company’s stock after selling 3,688 shares during the quarter. Boltwood Capital Management’s holdings in Pfizer were worth $1,435,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Rialto Wealth Management LLC bought a new stake in Pfizer during the fourth quarter worth $26,000. Clarity Asset Management Inc. bought a new stake in Pfizer during the fourth quarter worth $27,000. Gould Capital LLC grew its holdings in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer during the fourth quarter worth $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer during the fourth quarter worth $30,000. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on PFE shares. UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Cantor Fitzgerald started coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective for the company. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Stock Up 0.3%

Shares of NYSE PFE opened at $23.42 on Thursday. The business’s fifty day moving average price is $23.02 and its 200-day moving average price is $25.02. The stock has a market capitalization of $133.15 billion, a PE ratio of 16.61, a P/E/G ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.82 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.34%. Pfizer’s dividend payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.